VEXIM Launches Interface™, a New Biomaterial for Fixation Promoting Bone Repair

Regulatory News :

Today, Vexim (Paris:ALVXM) (FR0011072602 - ALVXM), a medical device company specialized in minimally invasive treatment of vertebral fractures announces the launch of Interface™¹, an innovative new biomaterial for bone fixation.

A biomaterial perfectly suited for young patients

Interface™ is a biological alternative to existing orthopedic cements for treating traumatic vertebral fractures in patients with good bone quality. Used with SpineJack®, Interface™ preserves the existing bone tissue. The injection of this biomaterial permits optimal stabilizing of the vertebral body while facilitating bone remodeling. This osseointegration results from Interface™’s specific formula, composed of 50% hydroxyapatite particles, with a formulation very close to bone structures.

Developed by VEXIM, Interface™ cement has the same physical properties as the well-known and widely used cement, Cohesion®:

• Very high viscosity, reducing the risk of leakages;
• Optimal working time before hardening, making it safer for surgeons to inject;
• High radiopacity, allowing its deployment in the vertebra to be monitored with precision.

Thanks to the bioactive properties of Interface™ cement, VEXIM is strengthening its competitive advantage in younger patients, particularly in the traumatic fracture segment.

Vincent Gardès, CEO of VEXIM, states: "We are happy to provide surgeons with this new biomaterial, which improves the care of patients with traumatic bone fracture. Its development builds on the mechanical qualities of our Cohesion® cement, mainly designed for osteoporotic and tumor-related fractures, while improving osseointegration qualities, in order to target patients with high reossification potential, primarily young ones. In this way, we provide a range of advanced biomaterials, suitable for all types of vertebral compression fractures and sold in all our European markets.”

***

Next press releases:

• 2013 annual sales: January 2014
• 2013 annual results: March 2014

About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital² and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 50 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3^rd 2012.
For further information, please go to www.vexim.com

SpineJack®¹, a revolutionary implant for treating Vertebral Compression Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.
SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

• Name: VEXIM
• ISIN code: FR0011072602
• Ticker: ALVXM

¹ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.

² Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.